Packera aurea

ImmunoGen Presents Initial Findings From the Phase 1b/2 Study of IMGN632 in Combination With Vidaza® and Venclexta® in Relapsed/Refractory Acute Myeloid Leukemia at ASH

Retrieved on: 
Sunday, December 12, 2021
Oncology, Health, Stem Cells, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, CCR, U.S. Securities and Exchange Commission, Control, FDA, AML, Lymphatic system, BPDCN, Company, Azacitidine, CRC, ImmunoGen, IMGN, CD123, Population, CR, Toxicity, IGN, Industry, ORR, Venetoclax, COVID-19, Cancer, Blastic plasmacytoid dendritic cell neoplasm, ADC, Annual report, Acute leukemia, Packera aurea, 2021 Essex County Council election, Anemia, Safety, Patient, Disease, Capillary leak syndrome, Department, DNA, University, Associate, Security (finance), FLT3, Bone marrow, Lymphoma, MD Anderson Cancer Center, MD, Leukemia, Acute myeloid leukemia, ASH, Infection, Pancreatic serous cystadenoma, ALL, Skin, Senior, Society, Genta (company), Vaccine, Pharmaceutical industry, Copper, Sintering

Data for IMGN632 in frontline patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) were also presented in a poster session at the conference.

Key Points: 
  • Data for IMGN632 in frontline patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) were also presented in a poster session at the conference.
  • IMGN632 continued to display a manageable safety profile in R/R AML patients.
  • "We look forward to further exploring the safety and efficacy of this triplet in Phase 2 expansion cohorts planned for next year.
  • CD123, the interleukin-3 alpha chain, is expressed on multiple myeloid and lymphoid cancers including AML, BPDCN, ALL, chronic myeloid leukemia, and myeloproliferative neoplasms.

InsightRX's Precision Medicine Technology to Help Improve Care for Patients Receiving Stem Cell Transplants

Retrieved on: 
Monday, November 22, 2021
Patient, Tissue, University of California, San Francisco, CEO, SOS, Cancer, Vein graft failure, Leukemia, Busulfan, Chronic myelogenous leukemia, Death, ATG, AML, Health, Packera aurea, Precision medicine, Transplant, Acute myeloid leukemia, Doctor of Philosophy, SAN, MSK, University, Metabolism, UCSF, Machine learning, Memorial Sloan Kettering Cancer Center, Research, CML, Apollo, Adult, Degenerative disease, Here Comes the Sun, Mortality, Pharmacy, Graft-versus-host disease, Infection, San Francisco, Liver, Lymphatic system, Pharmaceutical industry

The InsightRX Nova platform helps to select patient-specific doses of the chemotherapy drugs busulfan and fludarabine, as well as the immunosuppressant anti-thymocyte globulin (ATG), for adult and pediatric patients receiving stem cell transplants.

Key Points: 
  • The InsightRX Nova platform helps to select patient-specific doses of the chemotherapy drugs busulfan and fludarabine, as well as the immunosuppressant anti-thymocyte globulin (ATG), for adult and pediatric patients receiving stem cell transplants.
  • Stem cell transplants typically are preceded by a chemotherapeutic conditioning regimen that destroys cancer cells and suppresses a patient's immune response to the donor cells.
  • The five-year cumulative mortality rate for leukemia patients receiving a stem cell transplant is about 50%, with relapse, infection, and GvHD as the leading causes of death.
  • InsightRX is a healthcare technology company that has developed a cloud-based platform for precision medicine and clinical analytics designed to individualize treatment at the point of care.

ImmunoGen to Present Initial Data Combining IMGN632 with Vidaza® and Venclexta® in Relapsed/Refractory Acute Myeloid Leukemia at ASH

Retrieved on: 
Thursday, November 4, 2021
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Safety, MD, 2021 Essex County Council election, Capillary leak syndrome, IGN, CCR, Cancer, Anemia, Disease, Leukemia, Industry, Control, Blastic plasmacytoid dendritic cell neoplasm, FLT3, BPDCN, ADC, Infection, Security (finance), U.S. Securities and Exchange Commission, Patient, Private Securities Litigation Reform Act, Pancreatic serous cystadenoma, IRR, FDA, View, Bone marrow, Acute leukemia, Abstract, Genta (company), ORR, ALL, ASH, Breathe Me, CD123, Lymphoma, Lymphatic system, CRC, Azacitidine, Senior, Annual report, Company, Fatigue, COVID-19, Skin, Acute myeloid leukemia, Packera aurea, CR, Program, Novel, AML, DNA, Toxicity, Population, IMGN, Febrile neutropenia, Society, Hypophosphatemia, ImmunoGen, Pneumonia, Vaccine, Pharmaceutical industry

These data will be presented in an oral session at the 63rd American Society of Hematology (ASH) Annual Meeting December 11-14.

Key Points: 
  • These data will be presented in an oral session at the 63rd American Society of Hematology (ASH) Annual Meeting December 11-14.
  • Data for IMGN632 in frontline patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) will also be presented in a poster session at ASH.
  • IMGN632 is a CD123-targeting ADC in clinical development for hematological malignancies, including blastic plasmacytoid dendritic cell neoplasm (BPDCN), acute myeloid leukemia (AML), and other CD123+ hematologic malignancies.
  • CD123, the interleukin-3 alpha chain, is expressed on multiple myeloid and lymphoid cancers including AML, BPDCN, ALL, chronic myeloid leukemia, and myeloproliferative neoplasms.

Saladax Biomedical and InsightRX to Present Chemotherapy Drug Outcomes at International Congress in September

Retrieved on: 
Tuesday, September 14, 2021
Precision medicine, Patient safety, International Congress on Tuberculosis, SAN, CEO, Technology, Health, Packera aurea, Doctor of Philosophy, Patient, Mortality, Safety, Machine learning, Oncology, Acute leukemia, Partnership, Center, Therapeutic drug monitoring, Disease, Research, Cancer, Bone marrow, Congress, Pharmaceutical industry, Medical imaging, Medical device

During the Congress, InsightRX and Saladax will be presenting the results of a solution that combines Saladax's MyCareassay kit with InsightRX's precision dosing technology to individualize Busulfan therapy.

Key Points: 
  • During the Congress, InsightRX and Saladax will be presenting the results of a solution that combines Saladax's MyCareassay kit with InsightRX's precision dosing technology to individualize Busulfan therapy.
  • Busulfan is a chemotherapy drug for the treatment of chronic myeloid leukemia, a type of cancer that starts in blood-forming cells of the bone marrow.
  • "For a number of reasons, measuring busulfan is a challenging process," said Salvatore J. Salamone, PhD, President and CEO of Saladax.
  • Saladax and InsightRX will be presenting their findings at the Congress in Rome, Italy.

Global microRNA (miRNA) Market Analysis Report 2021: Focus on Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 17, 2021
Infectious Diseases, Health, Oncology, Blood pressure, Packera aurea, Growth, Therapy, MicroRNA, Adoption, Prognosis, Fluid mechanics, Diagnosis, Biomarker, Research, Bipolar II disorder, Asia, Investment, Mirna, Neurodegeneration, Hypertension, Genomics, Goal, NGS, Proteomics, Medical imaging, Pharmaceutical industry

The "microRNA Market Share, Size, Trends, Industry Analysis Report, By Product; By Services; By Application; By End-Use; By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "microRNA Market Share, Size, Trends, Industry Analysis Report, By Product; By Services; By Application; By End-Use; By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • The rising adoption of microRNA as a biomarker is driving the market.
  • Moreover, growing interest in liquid-based biopsies has further led to its increased importance in biomarker discovery and further development.
  • In addition, a market study has also paved several computational tools to predict the relation between miRNA and its target microRNA.